INVESTOR ALERT: Securities Class Action Filed Against Insulet Corporation – Investors Encouraged to Contact Kirby McInerney LLP
Kirby McInerney LLP has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements by failing to disclose defective manufacturing controls that led to product safety violations and recalls. Investors who suffered losses are encouraged to contact the firm to discuss lead plaintiff appointment, with a deadline of August 31, 2026.
PODD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Insulet Investors of Securities Class Action Lawsuit Deadline on August 31, 2026
Faruqi & Faruqi, LLP is reminding Insulet Corporation (NASDAQ: PODD) investors of the August 31, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls, which led to two voluntary Medical Device Corrections for its Omnipod products and subsequent stock price declines. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, are encouraged to contact the firm for more information.
Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target
Deutsche Bank has initiated coverage on Insulet (NASDAQ: PODD) with a Buy rating and a $190 price target. Analyst Kieran Ryan sees Insulet as the dominant player in the tubeless insulin pump market with strong growth potential, despite rising competition and pharmacy channel pressure. The analyst believes current fears regarding GLP-1 weight-loss drugs and their impact on diabetes device stocks are exaggerated and already factored into Insulet's valuation.
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Insulet Corporation (PODD) Shareholders To Inquire About Securities Fraud Class Action
Glancy Prongay Wolke & Rotter LLP has filed a securities fraud class action lawsuit against Insulet Corporation (PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements and failed to disclose defective manufacturing controls, which led to multiple voluntary Medical Device Corrections and significant drops in the company's stock price. Shareholders have until August 31, 2026, to file a lead plaintiff motion.
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With Large Losses in Insulet Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased shares between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements about its business operations, growth, and financial stability, leading to inflated stock prices and significant losses for investors. Affected investors are encouraged to contact Bernstein Liebhard LLP by August 31, 2026, to discuss their rights or to serve as lead plaintiff.
Insulet Misled Investors on Manufacturing Procedures, Suit Says
A proposed class-action lawsuit alleges that Insulet Corp. and its executives made false statements to investors regarding the company's manufacturing controls. The suit claims Insulet failed to disclose defective manufacturing procedures, which concealed the risk of their products violating safety regulations or causing injury. This alleged misleading conduct was highlighted by former CEO James Hollingshead's statements in a February earnings call.
Insulet Misled Investors on Manufacturing Procedures, Suit Says
A proposed class-action lawsuit alleges that Insulet Corp. and its executives made false statements to investors regarding the company's manufacturing controls. The suit, filed in Massachusetts, claims Insulet failed to disclose defective manufacturing procedures, thereby concealing risks of product safety violations or injury hazards from investors.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain executives, alleging violations of federal securities laws. Filed by Bronstein, Gewirtz & Grossman, LLC, the suit claims defendants made misleading statements about the company's business and compliance, specifically regarding defective manufacturing controls. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the lawsuit, with an August 31, 2026, deadline to apply for lead plaintiff.
PODD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Insulet Corporation Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm
Holzer & Holzer, LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) alleging that the company made false and misleading statements regarding its business operations and compliance policies. Specifically, the lawsuit claims that Insulet's manufacturing controls were defective, leading to a heightened risk of product safety violations or injuries. Investors who purchased Insulet shares between February 21, 2025, and May 26, 2026, and experienced losses are encouraged to contact the firm, with an August 31, 2026, deadline to seek appointment as lead plaintiff.
Evercore ISI Adjusts Price Target on Insulet to $180 From $200
Evercore ISI has adjusted its price target for Insulet (PODD) to $180 from $200. This update indicates a revised outlook from the financial firm on the medical equipment company's stock. The article also mentions Insulet's recent expansion into Spain and other analyst adjustments to its price target.
Insulet launches Omnipod 5 insulin system in Spain
Insulet Corporation has commercially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making Spain the 20th country where Omnipod 5 is available. The system is designed for individuals aged two and older with type 1 diabetes and is compatible with Abbott’s FreeStyle Libre 2 Plus and Dexcom’s G7 sensors. Insulet is also working with Spanish health authorities to ensure market access while continuing its aggressive international expansion.
Insulet launches Omnipod 5 insulin system in Spain By Investing.com
Insulet Corporation has officially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making it the 20th country for Omnipod 5 and 26th market overall for Insulet's Omnipod products. This expansion targets Spain's 189,000 individuals with type 1 diabetes, enabling automated insulin delivery and data management for better diabetes care. Despite the aggressive international growth and 32% revenue increase, InvestingPro analysis suggests the stock is currently overvalued, while the company also faces recent product recall concerns and new analyst coverage.
Insulet launches Omnipod 5 and Omnipod Discover in Spain
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking its availability in the 26th country overall and 20th for Omnipod 5. The Omnipod 5 system is designed for type 1 diabetes patients aged two and older, automatically adjusting insulin delivery and being compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 CGMs. Omnipod Discover is a web-based platform for data analytics aimed at improving therapy discussions.
Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover™ in Spain, marking Spain as the 20th country where Omnipod 5 is available. This expansion aims to provide tubeless diabetes management technology to the more than 4.6 million adults with diabetes in Spain, including approximately 189,000 individuals with type 1 diabetes. Omnipod 5 simplifies insulin management by automatically adjusting delivery, while Omnipod Discover provides actionable insights from diabetes data for users and healthcare providers.
Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover in Spain, marking its 26th country of operation and the 20th for Omnipod 5. This expansion aims to provide tubeless diabetes technology to over 4.6 million adults with diabetes in Spain, including approximately 189,000 individuals with type 1 diabetes. Omnipod 5 is designed to simplify diabetes management by automatically adjusting insulin delivery, while Omnipod Discover offers a data analytics platform for personalized care and therapy discussions.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel ...
Rosen Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls, which created a foreseeable risk of products violating safety regulations or posing injury risks. Investors are encouraged to secure qualified counsel and can join the lawsuit by August 31, 2026, to potentially serve as lead plaintiff.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD
Rosen Law Firm is encouraging investors of Insulet Corporation (NASDAQ: PODD) to secure counsel before the August 31, 2026 deadline in a securities class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements regarding defective manufacturing controls and foreseeable risks of injury, causing investors damages. Investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, may be entitled to compensation.
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit on behalf of Insulet Corporation (NASDAQ: PODD) stockholders who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made false and misleading statements and/or failed to disclose that its manufacturing controls and procedures were defective, leading to a foreseeable risk of product safety violations. Stockholders with significant losses are encouraged to contact the firm to learn about their rights and potentially participate as lead plaintiffs by August 31, 2026.
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made false or misleading statements regarding defective manufacturing controls, creating a risk of product violations and injury. Stockholders with significant losses are encouraged to contact the firm to learn about their rights and the option to serve as lead plaintiff by August 31, 2026.
FinancialContent - Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements and failed to disclose defective manufacturing controls, which created a risk of safety violations. Shareholders with significant losses are encouraged to contact the firm to learn about their rights and the process for serving as a lead plaintiff by August 31, 2026.
Rosen Law Firm Urges Insulet Corporation (NASDAQ: PODD) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm has announced a class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made misleading statements regarding defective manufacturing controls and procedures. Shareholders who suffered losses are urged to contact Rosen Law Firm and must file to serve as lead plaintiff by August 31, 2026.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, healthcare stocks are gaining attention as investors rotate out of semiconductor and AI sectors. The report highlighted job growth primarily in healthcare, prompting a focus on resilient companies in this market. This article identifies three healthcare stocks—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that appear well-positioned for the current economic climate, offering insights into their operations, market positions, and growth prospects.
PODD Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Insulet Corporation
Robbins LLP is reminding investors of a class action lawsuit against Insulet Corporation (NASDAQ: PODD) for allegedly misleading investors about defective manufacturing controls and procedures. The lawsuit stems from two voluntary medical device corrections in March and May 2026 for Omnipod products, which led to significant drops in Insulet's stock price. Shareholders who purchased Insulet securities between February 21, 2025, and May 26, 2026, are encouraged to contact Robbins LLP to learn about their options.
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025, and May 26, 2026, to contact them regarding a class action lawsuit. The lawsuit alleges that Insulet made false and misleading statements about defective manufacturing controls and safety violations, which led to a March 2026 Medical Device Correction impacting more Pod Products than disclosed. Investors who suffered losses have until August 31, 2026, to seek to become lead plaintiffs in the lawsuit.
PODD Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Insulet Corporation
Robbins LLP is reminding investors of a class action lawsuit against Insulet Corporation (NASDAQ: PODD) for allegedly misleading investors about the viability of its products. The lawsuit claims Insulet's manufacturing controls were defective, leading to product recalls and significant drops in the company's stock price. Shareholders who purchased Insulet securities between February 21, 2025, and May 26, 2026, may be eligible to participate in the class action.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Insulet made false and misleading statements about its manufacturing controls and procedures, creating a risk of product safety violations. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case, with an August 31, 2026, deadline to request lead plaintiff appointment.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet made materially false and misleading statements regarding its business, operations, and compliance policies, specifically concerning defective manufacturing controls. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case and have until August 31, 2026, to request lead plaintiff appointment.
Bronstein, Gewirtz & Grossman LLC Urges Insulet Corporation Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and some of its officers, alleging violations of federal securities laws. The lawsuit claims that Insulet made materially false and misleading statements regarding defective manufacturing controls and procedures, creating a foreseeable risk of safety violations. Investors who purchased Insulet securities between May 21, 2025, and May 26, 2026, are encouraged to join the case and have until August 31, 2026, to request to be appointed as lead plaintiff.
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)
Grabar Law Office is investigating claims against Insulet Corporation (NASDAQ: PODD) on behalf of shareholders who purchased shares prior to February 21, 2025, alleging breaches of fiduciary duties by certain officers and directors. The investigation stems from alleged false and misleading statements regarding defective manufacturing controls that led to voluntary Medical Device Corrections for Omnipod products in March and May 2026 due to potential insulin under-delivery. Shareholders who held shares before February 21, 2025, can seek corporate reforms and the return of funds, while those who purchased between February 21, 2025, and May 26, 2026, may participate in a class action.
TNDM - Tandem Diabetes Care Inc Options
This article provides a detailed financial overview of Tandem Diabetes Care Inc. (TNDM), including its last closing price, market capitalization, key financial ratios, earnings per share, sales performance, and insider/institutional ownership. It also presents various performance metrics across different timeframes and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
FDA Classifies Insulet’s Omnipod Correction As Class I Recall Over Cannula Defect
The FDA has classified a correction to Insulet's Omnipod systems as a Class I recall due to a cannula defect. This recall impacts all three generations of the company's pod-based systems, including the Omnipod 5, Omnipod DASH, and the original Omnipod (Eros). The company has faced previous issues, with serious injuries tied to Omnipod patches and a prior recall over a tubing tear.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, investors are shifting focus to the healthcare sector for resilience as other markets become uncertain. This article highlights three healthcare stocks – Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD) – that offer diverse opportunities, from specialized biopharmaceuticals to medical devices and global biopharma. These companies are generating interest due to their potential for growth, strong financials, or critical market positioning amidst the changing economic landscape.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak US jobs report in June, investors are shifting focus to healthcare stocks, moving away from semiconductor and AI sectors. This article highlights three healthcare companies—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that are well-positioned for resilience amidst economic uncertainties. Each company offers unique strengths, from pipeline advancements and recurring revenue models to strong market presence and dividends, making them attractive in the current investment climate.
Insulet Stock: A High-Quality Growth Story At A Reasonable PEG (NASDAQ:PODD)
Insulet (PODD) is rated a Buy due to its strong growth, low market penetration in diabetes management, and a recurring revenue model. The company's Omnipod system offers simplified diabetes care, driving sales and reducing patient burden. Despite concerns about GLP-1 drugs, Insulet targets insulin-dependent patients with significant room for growth, projecting a 60% upside to $260–270, supported by a 21% sales CAGR and a favorable PEG ratio compared to peers.
Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD
Pomerantz LLP has filed a class action lawsuit against Insulet Corporation and certain officers on behalf of investors who purchased Insulet securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet made materially false and misleading statements regarding its manufacturing controls, leading to product issues with its Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System. Investors have until August 31, 2026, to apply for lead plaintiff.
Investor Notice: Robbins LLP Informs Investors of the Insulet Corporation Securities Class Action Lawsuit
Robbins LLP is informing investors of a securities class action lawsuit filed against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet misled investors about defective manufacturing controls which led to product recalls and a significant drop in stock price. Shareholders who purchased Insulet securities between February 21, 2025, and May 26, 2026, may be eligible to participate and are encouraged to contact Robbins LLP to serve as lead plaintiff.
Insulet (PODD) director receives 144 deferred stock units as compensation
Insulet (PODD) director Robert Luther Huffines was granted 144 deferred common stock units, valued at $159.79 per unit, as non-cash compensation. These units will convert into common shares on a one-for-one basis upon distribution, increasing his direct holdings to 2,442 shares. The distribution of shares will occur either as a lump sum or in substantially equal annual installments, as per the director's election under the Company's Deferred Compensation Plan for Non-Employee Directors.
Insulet (NASDAQ: PODD) director files Form 3 showing no share holdings
Jonathan Jay Mazelsky, a director at Insulet (NASDAQ: PODD), filed an initial Form 3, which indicates he currently holds no shares of the company's common stock. This filing is a mandatory administrative disclosure for new insiders and does not signify any recent buy or sell transactions. It establishes his ownership status as zero shares following his appointment as a director.
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential legal claims on behalf of Insulet Corporation (NASDAQ: PODD) purchasers. This stems from Insulet's disclosure on March 12, 2026, about a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods due to a manufacturing issue, which led to a 6.88% stock price drop. The firm encourages affected shareholders to contact them to learn more about the investigation.
Law Offices of Howard G. Smith Encourages Insulet Corporation (PODD) Shareholders to Inquire About Securities Fraud Class Action
The Law Offices of Howard G. Smith has filed a class action lawsuit on behalf of Insulet Corporation (PODD) investors who purchased securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet failed to disclose manufacturing issues with its Omnipod products, leading to significant stock price drops following two voluntary Medical Device Corrections. Investors injured by these disclosures are encouraged to contact the firm to participate in the securities fraud lawsuit.
Insulin pump makers Tandem and Insulet post contrasting Q2 results
Tandem Diabetes Care and Insulet, two major insulin pump manufacturers, have reported contrasting financial results for the second quarter. While Tandem saw a decline in its pump shipments and revised its full-year guidance downwards, Insulet exceeded revenue expectations and raised its outlook for the year due to strong demand for its Omnipod 5 system. This highlights a divergence in performance within the insulin delivery device market.
Insulin pump makers Tandem and Insulet post contrasting Q2 results
This article examines the contrasting Q2 results of insulin pump manufacturers Tandem and Insulet. It delves into the specific financial performance and key factors that led to different outcomes for each company during the quarter.
Insulet Corp. stock outperforms competitors on strong trading day
Insulet Corp. (PODD) saw its stock price rally 2.94% to $164.48, outperforming a mixed trading day for the broader market. This marks the second consecutive day of gains for Insulet, contrasting with the S&P 500 Index which remained mostly unchanged and the Dow Jones Industrial Average which rose 1.14%.
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
Insulet Corporation (NASDAQ: PODD) announced it will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, before the financial markets open. The company will also host a conference call at 8:00 a.m. (Eastern Time) on the same day to discuss the results, with access details available on their investor relations website. Insulet is a global leader in tubeless insulin pump technology with its Omnipod® brand.
Enterprise value to EBITDA forward of Insulet Corporation – NASDAQ:PODD
This page provides financial data for Insulet Corporation (NASDAQ: PODD), specifically its enterprise value to EBITDA forward. The data is available through TradingView, which offers various financial tools and market data services. The page focuses on the company's financials within the Medical Specialties sector.
Enterprise value to EBITDA forward of Insulet Corporation – XETR:GOV
This article focuses on the enterprise value to EBITDA forward for Insulet Corporation, traded on XETR as GOV. It provides a snapshot of the company's financials within the TradingView platform, specifically detailing metrics and market data access. The content is primarily a data placeholder rather than an in-depth analysis.
Insulet Corp. stock outperforms competitors on strong trading day
Shares of Insulet Corp. (PODD) rallied 4.95% to $159.79 on Wednesday, outperforming the broader market during a tough trading session where both the S&P 500 and Dow Jones Industrial Average declined. This rise broke a two-day losing streak for the stock.
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
Insulet Corporation announced it will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, before financial markets open. Following the release, the company will host a conference call at 8:00 a.m. Eastern Time, with details for accessing the live call and replay available on its Investor Relations website. Insulet, known for its Omnipod tubeless insulin pump technology, continues to innovate in diabetes care.
Insulet will report Q2 results Aug. 5, with a call at 8 a.m.
Insulet Corporation announced it will report its second-quarter 2026 financial results on August 5, 2026, before financial markets open. The company will host a conference call at 8:00 a.m. ET to discuss the results, with details available on its investor relations website. Insulet is known for its Omnipod tubeless insulin pump technology, designed to simplify diabetes management.
GlobalFoundries lines up Aug. 5 call after Q2 results
GlobalFoundries (NASDAQ: GFS) has announced it will host a conference call on Wednesday, August 5, 2026, at 8:30 a.m. ET to discuss its second-quarter 2026 financial results. The financial results and a live webcast will be available on the company's investor relations website. Historically, similar earnings call scheduling announcements have led to a modestly positive stock price reaction for GFS.
